Studies have shown that the COX-2 inhibitor celecoxib inhibits IDO-mediated immune tolerance through regulatory T cells as well as suppresses the Interferon-γ-Induced expression of indoleamine 2,3-dioxygenase (IDO) in human leukemia cell lines (251, 252). This evidence concerns the gene IDO1 and leukemia.